Published in Lancet Infect Dis on January 01, 2006
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 6.59
Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis (2011) 1.64
Association of oncogenic and nononcogenic human papillomavirus with HIV incidence. J Acquir Immune Defic Syndr (2010) 1.54
Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics (2009) 1.45
Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog (2008) 1.44
Ladies first: should boys be vaccinated against HPV? Can Fam Physician (2008) 1.39
Male circumcision and penile cancer: a systematic review and meta-analysis. Cancer Causes Control (2011) 1.38
Anal HPV infection in HIV-positive men who have sex with men from China. PLoS One (2010) 1.37
Human papillomavirus detection by penile site in young men from Kenya. Sex Transm Dis (2007) 1.28
Meta-analysis of human papillomavirus infection concordance. Cancer Epidemiol Biomarkers Prev (2010) 1.25
Anal human papillomavirus infection among HIV-infected and uninfected men who have sex with men in Beijing, China. J Acquir Immune Defic Syndr (2013) 1.10
Epidemiology of oral human papillomavirus infection. Oral Oncol (2013) 1.07
Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis (2011) 1.05
Ensuring access to HPV vaccines through integrated services: a reproductive health perspective. Bull World Health Organ (2007) 0.98
Male human papillomavirus prevalence and association with condom use in Brazil, Mexico, and the United States. J Infect Dis (2012) 0.94
Human papillomavirus genital infections among men, China, 2007-2009. Emerg Infect Dis (2013) 0.91
Human papillomavirus clearance among males is associated with HIV acquisition and increased dendritic cell density in the foreskin. J Infect Dis (2013) 0.90
Human papillomavirus infection in a male population attending a sexually transmitted infection service. PLoS One (2013) 0.85
High-risk human papillomavirus viral load and persistence among heterosexual HIV-negative and HIV-positive men. Sex Transm Infect (2014) 0.85
Human papillomavirus in men: an update. J Low Genit Tract Dis (2011) 0.84
Prevalence of DNA-HPV in male sexual partners of HPV-infected women and concordance of viral types in infected couples. PLoS One (2012) 0.81
The role of sexual behavior in head and neck cancer: implications for prevention and therapy. Expert Rev Anticancer Ther (2014) 0.81
Penile, urethral, and seminal sampling for diagnosis of human papillomavirus infection in men. J Clin Microbiol (2006) 0.80
Where to begin human papillomavirus vaccination? Lancet Infect Dis (2006) 0.80
Human papillomavirus disease and vaccines in adolescents. Adolesc Med State Art Rev (2010) 0.80
Inhibition of human papillomavirus DNA replication by an E1-derived p80/UAF1-binding peptide. J Virol (2012) 0.80
Laboratory and clinical aspects of human papillomavirus testing. Crit Rev Clin Lab Sci (2012) 0.80
High-risk human papillomavirus prevalence is associated with HIV infection among heterosexual men in Rakai, Uganda. Sex Transm Infect (2012) 0.79
HPV related diseases in males: a heavy vaccine-preventable burden. J Prev Med Hyg (2013) 0.79
Anal dysplasia screening: an evidence-based analysis. Ont Health Technol Assess Ser (2007) 0.78
Mental representations of HPV in Appalachia: gender, semantic network analysis, and knowledge gaps. J Health Psychol (2011) 0.78
Programmed death-1 (PD-1)-dependent functional impairment of CD4(+) T cells in recurrent genital papilloma. Clin Exp Med (2013) 0.77
Rome Consensus Conference - statement; human papilloma virus diseases in males. BMC Public Health (2013) 0.77
Human papilloma virus (HPV) vaccination in childhood: challenges and perspectives. Hippokratia (2011) 0.76
Oral human papillomavirus infection in men might contribute to HPV serology. Eur J Clin Microbiol Infect Dis (2014) 0.76
Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection. Sex Transm Dis (2009) 0.76
Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world? Ann Med Health Sci Res (2013) 0.76
Transmission of human papillomavirus DNA from patient to surgical masks, gloves and oral mucosa of medical personnel during treatment of laryngeal papillomas and genital warts. Eur Arch Otorhinolaryngol (2012) 0.76
Analysis of human papillomavirus and herpes simplex virus genus -2 from patients with cervical cancer in isfahan, iran. Mater Sociomed (2014) 0.75
Human papillomavirus (HPV) infection: a Mozambique overview. Virusdisease (2016) 0.75
No clinical predictors of intraepithelial neoplasia in HIV-positive patients with external condilomata acuminata. Indian J Sex Transm Dis (2011) 0.75
Human papillomavirus DNA positivity and seropositivity in rural Chinese men and women: a population-based cross-sectional study. Sci Rep (2016) 0.75
Genital Human Papillomavirus Infection in Indian HIV-Seropositive Men Who Have Sex With Men. Sex Transm Dis (2017) 0.75
Oral and genital HPV genotypic concordance between sexual partners. Clin Oral Investig (2013) 0.75
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The epidemiology of human papillomavirus infections. J Clin Virol (2005) 3.63
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis (2008) 3.19
Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis (2004) 3.18
Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med (2008) 2.98
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst (2006) 2.67
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis (2006) 2.21
Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis (2002) 1.99
Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol (2003) 1.91
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev (2011) 1.74
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst (2009) 1.65
Obtaining sensitive data through the Web: an example of design and methods. Epidemiology (2002) 1.61
Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis (2012) 1.48
Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev (2007) 1.43
High rates of incident and prevalent anal human papillomavirus infection among young men who have sex with men. J Infect Dis (2013) 1.38
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev (2010) 1.34
p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol (2003) 1.27
Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age. Sex Transm Dis (2007) 1.27
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24
Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol (2006) 1.20
Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women. J Infect Dis (2009) 1.18
Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load. Cancer Epidemiol Biomarkers Prev (2009) 1.18
Detection of genital HPV types in fingertip samples from newly sexually active female university students. Cancer Epidemiol Biomarkers Prev (2010) 1.18
Men's perceptions and knowledge of human papillomavirus (HPV) infection and cervical cancer. J Am Coll Health (2005) 1.12
Human Papillomavirus (HPV) type 16 and type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-year follow-up. J Infect Dis (2009) 1.09
Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis (2008) 1.09
Determinants of cervical cancer rates in developing countries. Int J Cancer (2002) 1.08
Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis (2011) 1.08
Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. Am J Epidemiol (2004) 1.08
Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc (2005) 1.08
Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol (2009) 1.06
Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis (2009) 1.05
Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis (2011) 1.05
Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol (2011) 1.01
Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J Infect Dis (2008) 1.01
Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses. J Clin Microbiol (2009) 1.00
Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis (2010) 0.99
Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine (2004) 0.99
Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol (2005) 0.98
Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women. Sex Transm Dis (2012) 0.96
Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev (2002) 0.96
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer (2011) 0.95
Evaluation of dry and wet transport of at-home self-collected vaginal swabs for human papillomavirus testing. J Med Microbiol (2012) 0.95
Using risk factors to predict human papillomavirus infection: implications for targeted vaccination strategies in young adult women. Vaccine (2007) 0.95
Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obstet Gynecol (2009) 0.94
Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection. Cancer Epidemiol Biomarkers Prev (2006) 0.94
Inverse association between methylation of human papillomavirus type 16 DNA and risk of cervical intraepithelial neoplasia grades 2 or 3. PLoS One (2011) 0.94
Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine (2004) 0.94
Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis (2010) 0.93
Association of human papillomavirus type 31 variants with risk of cervical intraepithelial neoplasia grades 2-3. Int J Cancer (2012) 0.92
Evaluation of transported dry and wet cervical exfoliated samples for detection of human papillomavirus infection. J Clin Microbiol (2010) 0.91
Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage. Int J Cancer (2012) 0.90
Age of diagnosis of squamous cell cervical carcinoma and early sexual experience. Cancer Epidemiol Biomarkers Prev (2009) 0.90
Viral load and short-term natural history of type-specific oncogenic human papillomavirus infections in a high-risk cohort of midadult women. Int J Cancer (2013) 0.89
Characterization of IgA response among women with incident HPV 16 infection. Virology (2003) 0.89
Circumcision and acquisition of human papillomavirus infection in young men. Sex Transm Dis (2011) 0.87
Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in university women. J Clin Virol (2005) 0.86
Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol (2007) 0.86
Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int J Cancer (2007) 0.86
Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for a proper understanding of type-specific persistent infections. J Infect Dis (2010) 0.85
Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry? Obstet Gynecol (2002) 0.84
Risk of cervical intraepithelial neoplasia grade 2 or 3 after loop electrosurgical excision procedure associated with human papillomavirus type 16 variants. J Infect Dis (2007) 0.84
Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. Am J Obstet Gynecol (2008) 0.83
Prevalence of high-risk HPV types and abnormal cervical cytology in American Indian/Alaska Native women, 2003-2005. Public Health Rep (2011) 0.82
Human papillomavirus through the ages. J Infect Dis (2005) 0.81
Delivering reassurance to parents: perinatal human papillomavirus transmission is rare. Sex Transm Dis (2004) 0.81
Evaluation of an ELISA for p16INK4a as a screening test for cervical cancer. Cancer Epidemiol Biomarkers Prev (2009) 0.81
Disclosure of genital human papillomavirus infection to female sex partners by young men. Sex Transm Dis (2012) 0.81
Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections. J Infect Dis (2009) 0.81
Potential impact of human papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases. Sex Transm Dis (2007) 0.81
National burden of genital warts: a first step in defining the problem. Sex Transm Dis (2008) 0.79
The association of current hormonal contraceptive use with type-specific HPV detection. Sex Transm Infect (2011) 0.79
Sequence variation of human papillomavirus type 16 and measurement of viral integration by quantitative PCR. J Clin Microbiol (2008) 0.78
Should liquid-based cytology be repeated at the time of colposcopy? J Low Genit Tract Dis (2005) 0.77
Re: Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst (2004) 0.77
Determinants of High-Risk Human Papillomavirus Seroprevalence and DNA Prevalence in Mid-Adult Women. Sex Transm Dis (2016) 0.76
Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection. Sex Transm Dis (2009) 0.76
Epidemiology of Human Papillomavirus Detected in the Oral Cavity and Fingernails of Mid-Adult Women. Sex Transm Dis (2015) 0.75
Incidence of oral human papillomavirus infection. Lancet (2013) 0.75
Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005. Sex Transm Dis (2014) 0.75